PROGNOSTIC FACTORS IN PATIENTS WITH RELAPSED OR REFRACTORY SYSTEMIC ANAPLASTIC LARGE T-CELL LYMPHOMA (ALCL) RECEIVING BRENTUXIMAB VEDOTIN AND OUTCOME AFTER TREATMENT FAILURE.
Oki, Y., Feldman, T., Chihara, D., Sanchez, L., Fanale, M., Connors, J.M., Wong, S., Savage, K.J.Volume:
35
Language:
english
Journal:
Hematological Oncology
DOI:
10.1002/hon.2438_112
Date:
June, 2017
File:
PDF, 88 KB
english, 2017